M. Scurr

发表

Suppression of tumour-specific CD4+ T cells by regulatory T cells is associated with progression of human colorectal cancer

Geraint T. Williams, P. Mizen, A. Godkin, 2011, Gut.

Overcoming resistance to immunotherapy through multimodal approaches: is there hope for colorectal cancer?

A. Godkin, M. Scurr, 2020 .

Assessing the Prognostic Value of Preoperative Carcinoembryonic Antigen-Specific T-Cell Responses in Colorectal Cancer

R. Hills, A. Godkin, A. Gallimore, 2015, Journal of the National Cancer Institute.

Highly prevalent colorectal cancer-infiltrating LAP+ Foxp3− T cells exhibit more potent immunosuppressive activity than Foxp3+ regulatory T cells

K. Ladell, R. Hargest, A. Christian, 2013, Mucosal Immunology.

Elucidating the impact of CD4+ T cellson tumour progression in patientswith colorectal cancer

M. Scurr, 2013 .

T cell subsets and colorectal cancer: discerning the good from the bad.

A. Godkin, A. Gallimore, M. Scurr, 2012, Cellular immunology.

Whole blood-based measurement of SARS-CoV-2-specific T cell responses reveals asymptomatic infection and vaccine efficacy in healthy subjects and patients with solid organ cancers

M. Wills, A. Westwell, B. Morgan, 2021, medRxiv.

Whole blood‐based measurement of SARS‐CoV‐2‐specific T cells reveals asymptomatic infection and vaccine immunogenicity in healthy subjects and patients with solid‐organ cancers

M. Wills, A. Westwell, L. Fairclough, 2021, Immunology.

Response to COVID-19 booster vaccinations in seronegative people with multiple sclerosis

K. Schmierer, Angray S. Kang, N. Evangelou, 2022, Multiple Sclerosis and Related Disorders.

Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection.

Stephen R. Clark, Christopher P. Thomas, P. Taylor, 2011, Blood.

Magnitude of venous or capillary blood-derived SARS-CoV-2-specific T cell response determines COVID-19 immunity

R. Stanton, A. Godkin, J. Hindley, 2022, Nature Communications.

Cytomegalovirus-Specific IL-10-Producing CD4+ T Cells Are Governed by Type-I IFN-Induced IL-27 and Promote Virus Persistence

S. Clare, P. Ghazal, Simon A. Jones, 2016, PLoS pathogens.

Prognostic significance of interleukin-17A-producing colorectal tumour antigen-specific T cells

Å. Keita, A. Godkin, A. Gallimore, 2021, British Journal of Cancer.

Cancer Antigen Discovery Is Enabled by RNA Sequencing of Highly Purified Malignant and Nonmalignant Cells

R. Stanton, A. Parker, R. Hargest, 2020, Clinical Cancer Research.

Distinct bone marrow-derived and tissue resident macrophage-lineages proliferate at key stages during inflammation

P. Taylor, Simon A. Jones, F. Brombacher, 2013, Nature Communications.

Enhanced Detection of Antigen-Specific CD4+ T Cells Using Altered Peptide Flanking Residue Peptide–MHC Class II Multimers

A. Sewell, K. Ladell, G. Dolton, 2015, The Journal of Immunology.

MHC Class II Multimers - Residue Peptide T Cells Using Altered Peptide Flanking +Detection of Antigen-Specific CD4

A. Sewell, G. Dolton, A. Godkin, 2015 .

Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3

B. Vanhaesebroeck, L. Friedman, V. Kersemans, 2020, Journal for ImmunoTherapy of Cancer.

T‐cell modulation by cyclophosphamide for tumour therapy

A. Godkin, A. Gallimore, E. Campbell, 2018, Immunology.

The Ussing chamber system for measuring intestinal permeability in health and disease

Å. Keita, B. Srivastava, A. Godkin, 2019, BMC Gastroenterology.

The nature of the human T cell response to the cancer antigen 5T4 is determined by the balance of regulatory and inflammatory T cells of the same antigen-specificity: implications for vaccine design

R. Hargest, A. Christian, A. Greenshields-Watson, 2018, Cancer Immunology, Immunotherapy.

Low-Dose Cyclophosphamide Induces Antitumor T-Cell Responses, which Associate with Survival in Metastatic Colorectal Cancer

R. Hills, A. Godkin, A. Gallimore, 2017, Clinical Cancer Research.

Effect of Modified Vaccinia Ankara–5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer

R. Hills, A. Godkin, A. Gallimore, 2017, JAMA oncology.

MVA-5T4 immunotherapy (TroVax) and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): an open-label, randomized phase 1/2 clinical trial

Adams, R. Hills, Daniel, 2017 .

MVA-5T4 immunotherapy (TroVax) and low-dose cyclophosphamide for advanced colorectal cancer (TaCTiCC): an open-label, randomized phase 1/2 clinical trial

R. Hills, A. Godkin, A. Gallimore, 2017 .

Effect ofModified Vaccinia Ankara – 5 T 4 and Low-Dose Cyclophosphamide on Antitumor Immunity inMetastatic Colorectal Cancer A Randomized Clinical Trial

R. Hills, A. Godkin, A. Gallimore, 2017 .

Escalating Regulation of 5T4-Specific IFN-γ+ CD4+ T Cells Distinguishes Colorectal Cancer Patients from Healthy Controls and Provides a Target for In Vivo Therapy

R. Hargest, A. Christian, A. Godkin, 2013, Cancer Immunology Research.

Persistent COVID-19 Infection in Wiskott-Aldrich Syndrome Cleared Following Therapeutic Vaccination: a Case Report

M. Ponsford, S. Jolles, A. Godkin, 2021, Journal of clinical immunology.

COVID-19 vaccine response in people with multiple sclerosis.

K. Schmierer, Angray S. Kang, N. Evangelou, 2021, Annals of neurology.

Resolution of persistent SARS-CoV-2 infection with prolonged intravenous remdesivir and vaccination in a patient post CAR-T

J. Underwood, A. Godkin, C. Rowntree, 2023, International Journal of Hematology.

Response to COVID-19 booster vaccinations in seronegative people with MS.

K. Schmierer, N. Evangelou, G. Ingram, 2022, medRxiv.

Highly prevalent colorectal cancer-infiltrating LAP

K. Ladell, R. Hargest, A. Godkin, 2023 .

Esterified eicosanoids are acutely generated by 5-lipoxygenase in primary human neutrophils and in human and murine infection.

Stephen R. Clark, Christopher P. Thomas, P. Taylor, 2011, Blood.

Cancer antigen discovery is enabled by RNA-sequencing of highly 1 purified malignant and non-malignant cells 2

R. Hargest, K. Ashelford, A. Greenshields-Watson, 2020 .

Effect of Modified Vaccinia Ankara–5T4 and Low-Dose Cyclophosphamide on Antitumor Immunity in Metastatic Colorectal Cancer

R. Hills, A. Godkin, A. Gallimore, 2017, JAMA oncology.